Loading...
XKRX
016580
Market cap99mUSD
Jul 10, Last price  
10,000.00KRW
1D
2.15%
1Q
-3.57%
Jan 2017
-36.91%
Name

Whanin Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:016580 chart
P/E
11.23
P/S
0.60
EPS
890.49
Div Yield, %
3.06%
Shrs. gr., 5y
4.03%
Rev. gr., 5y
8.25%
Revenues
255.21b
-1.69%
80,091,447,00092,915,021,00099,386,536,000105,687,139,000110,052,051,320107,221,597,940104,479,910,140120,713,386,090145,397,202,330141,376,271,500147,953,429,460154,664,330,710159,176,971,650171,705,404,970177,775,700,610198,934,734,390230,393,578,986259,596,032,000255,214,382,000
Net income
13.60b
-41.85%
11,275,625,00011,154,237,00014,434,550,00017,236,908,00014,612,077,20015,796,562,80014,580,149,40018,805,535,45020,509,660,82016,397,455,15027,172,311,17021,517,959,15018,695,949,84023,387,790,17026,659,600,06023,921,351,11029,774,322,16923,380,719,00013,595,214,000
CFO
9.04b
-56.30%
9,578,987,0003,094,032,00018,607,208,00014,538,986,00015,115,299,99021,111,224,30010,666,757,40013,410,382,49015,927,221,68019,824,042,53023,479,839,41017,454,809,81024,730,950,63022,754,682,62035,317,945,23016,851,173,85023,196,782,38020,693,373,0009,043,600,000
Dividend
Dec 29, 2025300 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical enterprise specializing in the research, development, manufacturing, promotion, and distribution of therapeutic products. Their comprehensive portfolio encompasses treatments for mental health conditions (such as antidepressants and antipsychotics), neurological disorders (including nootropics, anti-dementia, and anti-epileptics), cardiovascular and gastrointestinal ailments, infectious diseases, allergies, pain and inflammation, metabolic imbalances, respiratory issues, and a variety of other central nervous system applications. Established in 1978, the company's corporate headquarters are situated in Seoul, South Korea.
URL
https://www.whanin.com/
IPO date
Jul 03, 1996
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT